

Paxillin (phospho Tyr118) antibody

Cat. No. GTX50155

Host	Rabbit
Clonality	Polyclonal
Isotype	lgG
Applications	WB, IHC-P
Reactivity	Human, Mouse

Package 100 μl

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	1:500-1:1000
IHC-P	1:50-1:100
No. 10 All Control of the control of	

Not tested in other applications.

Calculated MW 65 kDa. (Note)

Properties	
Form	Liquid
Buffer	PBS, 150mM NaCl, 50% Glycerol
Preservative	0.02% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Concentration	1 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	Peptide sequence around phosphorylation site of tyrosine 118 (H-V-Y(p)-S-F) derived from human Paxillin.
Purification	Purified by antigen-affinity chromatography. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
	Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.




For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 07 / 10 Page 1 of 2




DATA IMAGES



GTX50155 WB Image

WB analysis of extracts from 3T3 cells untreated or treated with serum using GTX50155 Paxillin (phospho Tyr118) antibody.



GTX50155 IHC-P Image

IHC-P analysis of human breast carcinoma tissue using GTX50155 Paxillin (phospho Tyr118) antibody.

Left: Primary antibody

Right: Primary antibody pre-incubated with the antigen specific peptide



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 07 / 10 Page 2 of 2